• Homepage
• About us
• Our Partners
• Research database
• Workshops
• Newsletters and resources
• Videos and Animations
• International Conferences
• Funding opportunities
• Search

I lead the group Advanced Drug Delivery and Biomaterials at the University of Louvain. After the definition of an unmet need, a multidisciplinary approach is used to design new drug delivery systems and demonstrate their efficacy and safety in vitro and in vivo. The main area of research is the design, characterisation and preclinical testing of nanomedicines, in particular for glioblastoma treatment. 

Existing collaborations relevant to drug delivery

Current collaborative projects on the treatment of glioblastoma focus on i) the local delivery of anticancer drugs in the resection cavity ii) targeted drug delivery using nanomedicines iii) immunotherapy and anticancer vaccines.

Publications relevant to drug delivery

Bastiancich C, Bianco J, Vanvarenberg K, Ucakar B, Joudiou N, Gallez B, Bastiat G, Lagarce F, Préat V, Danhier F. Injectable nanomedicine hydrogel for local chemotherapy of glioblastoma after surgical resection. J Control Release. 2017 Oct 28;264:45-54.

Bianco J, Bastiancich C, Jankovski A, des Rieux A, Préat V, Danhier F. On glioblastoma and the search for a cure: where do we stand? Cell Mol Life Sci. 2017 Jul;74(13):2451-2466.

Bastiancich C, Danhier P, Préat V, Danhier F. Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma. J Control Release. 2016 Dec 10;243:29-42.

Bastiancich C, Vanvarenberg K, Ucakar B, Pitorre M, Bastiat G, Lagarce F, Préat V, Danhier F. Lauroyl-gemcitabine-loaded lipid nanocapsule hydrogel for the treatment of glioblastoma. J Control Release. 2016 Mar 10;225:283-293

Fourniols T, Randolph LD, Staub A, Vanvarenberg K, Leprince JG, Préat V, des Rieux A, Danhier F. Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma. J Control Release. 2015 Jul 28;210:95-104.